Brand-specific enhanced safety surveillance of GSK’s Fluarix Tetra seasonal influenza vaccine in England: 2017/2018 season

References

• World Health Organisation (WHO). Influenza - burden of disease. [Accessed 2018 July]. http://www.who.int/influenza/surveillance_monitoring/bod/en/.
   Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Factsheet about seasonal influenza. [Accessed 2018 July]. https://ecdc.europa.eu/en/seasonal-influenza/facts/factsheet.
   Google Scholar
• World Health Organisation (WHO). Influenza - WHO recommendations on the composition of influenza virus vaccines. [Accessed 2018 July]. http://www.who.int/influenza/vaccines/virus/recommendations/en/.
   Google Scholar
• Knight M, Brocklehurst P, O’Brien P, Quigley MA, Kurinczuk JJ. Planning for a cohort study to investigate the impact and management of influenza in pregnancy in a future pandemic. Southampton (UK): NIHR Journals Library; 2015. doi:10.3310/hsdr03060.
   Google Scholar
• Yates L, Pierce M, Stephens S, Mill AC, Spark P, Kurinczuk JJ, Valappil M, Brocklehurst P, Thomas SH, Knight M. Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant. Health Technol Assess. 2010;14(34):109–82. doi:10.3310/hta14340-02.
   PubMed Web of Science ®Google Scholar
• National Health Service (NHS). The national flu immunisation programme 2017/18; 2017 [Accessed 2018 November]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/600880/annual_flu__letter_2017to2018.pdf.
   Google Scholar
• Pebody RG, Sinnathamby MA, Warburton F, Andrews N, Boddington NL, Zhao H, Yonova I, Ellis J, Tessier E, Donati M, et al. Uptake and impact of vaccinating primary school-age children against influenza: experiences of a live attenuated influenza vaccine programme, England, 2015/16. Euro Surveill. 2018;23:25. doi:10.2807/1560-7917.ES.2018.23.25.1700496.
   Google Scholar
• European Medicines Agency (EMA). Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU 2014. [Accessed 2018 July]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/04/WC500165492.pdf.
   Google Scholar
• European Medicines Agency (EMA). Guideline on influenza vaccines - non-clinical and clinical module; 2016 [Accessed 2018 July]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211324.pdf.
   Google Scholar
• Electronic Medicines Compendium. Fluarix tetra (GSK) - summary product characteristics; 2018 [Accessed 2018 July]. https://www.medicines.org.uk/emc/product/3021/smpc.
   Google Scholar
• de Lusignan S, Dos Santos G, Correa A, Haguinet F, Yonova I, Lair F, Byford R, Ferreira F, Stuttard K, Chan T. Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England. BMJ Open. 2017;7(5):e015469. doi:10.1136/bmjopen-2016-015469.
   PubMed Web of Science ®Google Scholar
• de Lusignan S, Ferreira F, Damaso S, Byford R, Pathirannehelage S, Yeakey A, Yonova I, Schuind A, Dos Santos G. Enhanced passive surveillance of influenza vaccination in England, 2016–2017- an observational study using an adverse events reporting card. Hum Vaccine Immunother. 2019;15(5):1048–59. doi:10.1080/21645515.2019.1565258.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline (GSK). European Medicines Agency (EMA) post-authorisation safety study of influenza vaccine; 2015 [Accessed 2019 January]. https://s3.amazonaws.com/ctr-gsk-7381/202055/6c71e2ba-2a3f-4080-8252-00c36ba23930/f3b2573d-fc7d-4b19-ba6d-1933c3a2562a/202055-Clinical-Study-Result-Summary-v1.pdf.
   Google Scholar
• Correa A, Hinton W, McGovern A, van Vlymen J, Yonova I, Jones S, de Lusignan S. Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profile. BMJ Open. 2016;6(4):e011092. doi:10.1136/bmjopen-2016-011092.
   PubMed Web of Science ®Google Scholar
• de Lusignan S, Correa A, Smith GE, Yonova I, Pebody R, Ferreira F, Elliot AJ, Fleming D. RCGP research and surveillance centre: 50 years’ surveillance of influenza, infections, and respiratory conditions. Br J Gen Pract. 2017;67(663):440–41. doi:10.3399/bjgp17X692645.
   PubMed Web of Science ®Google Scholar
• Public Health England (PHE). The green book - immunisation against infectious disease; 2013 [Accessed 2018 July]. https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book.
   Google Scholar
• Department for Communities and Local Government. The english indices of deprivation; 2015 [Accessed 2018 July]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/465791/English_Indices_of_Deprivation_2015_-_Statistical_Release.pdf.
   Google Scholar
• Jordan H, Roderick P, Martin D. The index of multiple deprivation 2000 and accessibility effects on health. J Epidemiol Community Health. 2004;58(3):250–57. doi:10.1136/jech.2003.013011.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: pilot study in England; 2019 [Accessed 2019 September]. https://clinicaltrials.gov/ct2/show/NCT03278067.
   Google Scholar
• GlaxoSmithKline (GSK). Study register - study 207781 description; 2019 [Accessed 2019 September]. https://www.gsk-studyregister.com/study/6031.
   Google Scholar
• Korn EL, Graubard BI. Confidence intervals for proportions with very small expected number of positive counts estimated from survey data. Surv Methodol. 1998;24:193–201. doi:12-001-X19980024356.
   Google Scholar
• National Health Service (NHS). Defining research - NRES guidance to help you decide if your project requires review by a research ethics committee; 2013 [Accessed 2018 July]. https://researchsupport.admin.ox.ac.uk/sites/default/files/researchsupport/documents/media/defining-research.pdf.
   Google Scholar
• Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004;57(2):121–26. doi:10.1046/j.1365-2125.2003.01875.x.
   PubMed Web of Science ®Google Scholar
• Bricout H, Chabanon AL, Souverain A, Sadorge C, Vesikari T, Caroe TD. Passive enhanced safety surveillance for vaxigrip and intanza 15 microg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16. Euro Surveill. 2017;22:18. doi:10.2807/1560-7917.ES.2017.22.18.30527.
   Google Scholar
• de Lusignan S, Correa A, Ellis J, Pebody R. Influenza vaccination: in the UK and across Europe. Br J Gen Pract. 2016;66(650):452–53. doi:10.3399/bjgp16X686677.
   PubMed Web of Science ®Google Scholar
• Dos Santos G, Yeakey A, Shende V, Smith K, Lin F, Zandman-van-Dijk E, Damaso S, Schmidt A. Passive enhanced safety surveillance of GSK’s quadrivalent seasonal influenza vaccine in Belgium, Germany and Spain, an observational study: protocol for the 2018/2019 influenza season. BMJ Open. 2019;9(8):e028043. doi:10.1136/bmjopen-2018-028043.
   PubMed Web of Science ®Google Scholar
• Dos Santos G. Challenges in implementing yearly enhanced safety surveillance of influenza vaccination in Europe: lessons learned and future perspectives. Hum Vaccin Immunother. 2019;15(11):2624–2636. doi:10.1080/21645515.2019.
   Web of Science ®Google Scholar